Arena Pharmaceuticals, Inc.
COMPOUNDS AND METHODS FOR TREATMENT OF NAFLD AND NASH

Abstract:

The present invention relates to 4-[6-(6-Methanesulfonyl-2-methyl-pyridin-3-ylamino)-5-methoxy-pyrimidin-4- -yloxy]-piperidine-1-carboxylic acid isopropyl ester (Compound 1), pharmaceutically acceptable salts, solvates, and hydrates thereof that modulate the activity of the GPR119 receptor. Compound 1 and pharmaceutical compositions thereof are directed to methods useful in the treatment of non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), and conditions related thereto.